How to get Wegovy in 2026: the four legitimate routes

Getting Wegovy is more straightforward than getting Ozempic, and the reason is a single regulatory fact: Wegovy is the semaglutide that is FDA-approved for chronic weight management, so you do not need a diabetes diagnosis to be prescribed it on-label.^[1] What you do need is to meet the label’s criteria and then pick a route to a prescription. There are four legitimate ones in 2026, and they differ mostly in who writes the script and what you end up paying. Here is the honest pathway, with prices verified from Novo Nordisk’s own pages as of mid-2026.

First, do you qualify on-label?

Wegovy is approved for adults with a body-mass index of 30 or higher (obesity), or 27 or higher (overweight) when paired with at least one weight-related condition such as high blood pressure, type-2 diabetes or high cholesterol.^[1] It is also approved for adolescents aged 12 and older at or above the 95th BMI percentile, and — following the SELECT cardiovascular outcomes trial — to reduce the risk of heart attack and stroke in adults with established cardiovascular disease who are overweight or obese.^[2] That last indication matters for coverage, because it is the lever that unlocks Wegovy under some plans that otherwise exclude weight-loss drugs. If you clear the BMI bar, every route below is open to you.

Route 1 — Your own doctor and insurance

The classic path: a primary-care physician or specialist confirms you meet the BMI criteria and writes the prescription. Because Wegovy is being used on-label, this is the route most likely to end in real insurance coverage — but coverage is far from automatic. Most commercial plans that cover Wegovy require prior authorization, where your clinician documents your BMI, any comorbidities, and sometimes prior attempts at lifestyle change before the plan approves the fill. Some plans add step therapy or exclude weight-loss drugs from the formulary entirely. When a plan does cover it, Novo’s savings offer can bring the copay to as little as $25 per 28-day fill, subject to a monthly maximum.^[3] The mechanics of prior authorization, formularies and what coverage actually looks like are covered in depth in our GLP-1 cost and insurance coverage explainer.

Route 2 — NovoCare Pharmacy direct self-pay

If you have no coverage, or your plan refuses Wegovy, Novo Nordisk sells it to you directly through NovoCare Pharmacy. This is the cleanest cash route, and the pricing is published. As of mid-2026, the injectable pen is $199/month for the first two months (an introductory offer running through June 30, 2026 on the 0.25 mg and 0.5 mg starting doses), then $349/month for standard doses, with the higher-strength Wegovy HD 7.2 mg pen at $399/month.^[3] The newer oral semaglutide pill starts at $149/month for the lower doses.^[4] You still need a prescription — NovoCare doesn’t write one — but once you have it, you can fill direct without going through your insurer at all. The full tier-by-tier breakdown lives in our Wegovy cost guide. One practical note: several of these prices carry hard expiration dates, so confirm the current figure on Novo’s site before you budget.

Route 3 — GLP-1 telehealth

If you don’t have a doctor you see regularly, or you want the eligibility check, prescribing and fulfillment handled in one place, a GLP-1 telehealth service can be the fastest route. You complete an online intake, a licensed clinician reviews whether you meet the criteria, and — if appropriate — they prescribe. The legitimate services prescribe brand-name Wegovy (often routed through NovoCare or your pharmacy) and charge a separate membership or visit fee on top of the drug cost. Quality varies widely, and the line between a real clinical service and a thin prescription mill matters here, so we vet them in our guide to GLP-1 providers. Treat any service promising Wegovy without a genuine clinical assessment, or pushing a suspiciously cheap “semaglutide,” as a red flag — which leads to the fourth route.

Route 4 — The compounded-semaglutide question

During the 2023–24 shortage, compounded semaglutide was everywhere and cheap, and many telehealth services were built on it. That door has largely closed. The FDA declared the semaglutide shortage resolved in early 2025, which ended the broad exemption that had let pharmacies mass-produce copies of a drug that is otherwise commercially available. In 2026 the FDA went further, proposing to exclude semaglutide (along with tirzepatide and liraglutide) from the bulk substances that outsourcing facilities may compound.^[5] Narrow, patient-specific compounding can still be legal when there is a documented clinical reason a patient cannot use the FDA-approved product — for example, a genuine allergy to an inactive ingredient — but a cheap “compounded semaglutide” subscription marketed as a discount version of Wegovy is operating in a shrinking, legally contested space. Before you go that way, read our compounded vs branded GLP-1 regulatory guide; for most people, the branded routes above are the safer and now often comparably affordable choice.

Does Wegovy actually work? The evidence behind the routes

It’s worth remembering what you’re going to the trouble for. In the pivotal STEP 1 trial, adults with overweight or obesity (without diabetes) on once-weekly semaglutide 2.4 mg lost an average of about 15% of body weight over 68 weeks, versus roughly 2.4% on placebo.^[1] In the SELECT cardiovascular outcomes trial, semaglutide 2.4 mg cut the risk of major adverse cardiovascular events by about 20% in people with established heart disease who were overweight or obese but did not have diabetes — the finding that underpins Wegovy’s cardiovascular indication.^[2] The fuller picture, including how the effect builds over time, is in our semaglutide weight-loss trials review and the semaglutide results timeline. If you’re weighing it against the higher-potency tirzepatide alternative, see Zepbound vs Wegovy.

Frequently asked questions

Do I need type-2 diabetes to get Wegovy? No. Unlike Ozempic, Wegovy is approved for chronic weight management, so a BMI of 30+ (or 27+ with a weight-related condition) qualifies you on-label.^[1]

Can I get the $25 copay without insurance? No. The $25 savings offer reduces a copay on a plan that already covers Wegovy; it cannot create coverage where there is none, and it excludes government insurance.^[3] If you’re uninsured, the NovoCare self-pay price is your number.

Is compounded semaglutide the same thing for less? No. It is not FDA-approved, the shortage that permitted mass compounding is over, and the FDA is moving to close the pathway entirely.^[5] A cheap “compounded Wegovy” subscription is not a settled, lower-cost version of the branded drug.

Which route is fastest? A reputable GLP-1 telehealth service usually compresses eligibility, prescribing and fulfillment into a few days; your own doctor plus a prior-authorization can take longer but is the route most likely to end in insurance coverage.

The honest bottom line

Wegovy is easier to get on-label than Ozempic because you don’t need diabetes — you need to meet the BMI criteria and choose a route. If your commercial plan covers it, go through your doctor and use the savings offer to land near $25 a month. If it doesn’t, NovoCare self-pay is the predictable cash route at $199/month for two months then $349 on the pen, or from $149 for the pill. Telehealth can be the fastest path when you want one-stop service, and compounded semaglutide is no longer a reliable or clearly legal discount. Start from the evidence in our semaglutide trials review, model the price in the Wegovy cost guide, and compare the legitimate prescribers in our best GLP-1 providers roundup.